Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Randomized Phase II Study of Everolimus (E) Versus Everolimus plus Bevacizumab (E plus B) in Patients (Pts) With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance) Kulke, M. H., Niedzwiecki, D., Foster, N. R., Fruth, B., Kunz, P. L., Kennecke, H., Wolin, E. M., Venook, A. P. LIPPINCOTT WILLIAMS & WILKINS. 2016: 477
View details for Web of Science ID 000370956600057